Total Pageviews

Saturday 9 August 2014

Why we promote low carb and minimal medication for type two diabetics.

Following a low carb high fat diet our diabetic type two friends are mostly medication free.Many have stayed medication free for over six years and almost all hold non diabetic HbA1c numbers. Some including me use Metformin, a drug considered safe and used for many years by countless  millions of type two diabetics. We have stayed well clear of other type two drugs. Read the information below and you will understand why. Please remember we are not talking about a guy with a blog, we are talking about information on the official NHS web site.


"The BMJ article also discusses lawsuits in the USA related to the possible link between exenatide and acute pancreatitis. This led to a judge allowing an independent pathologist to review the manufacturer's slides of slices of pancreas from monkeys treated with exenatide – the manufacturer reportedly initially refused access to these slides. The pathologist found more chronic inflammation and pancreatic disease in the treated monkeys than untreated controls.
A team from the University of California, Los Angeles (UCLA) analysed data from 2004-09 recorded in the FDA adverse event database. It found that the odds of pancreatitis were increased about six- to tenfold with exenatide and sitagliptin, and the odds of pancreatic cancer increased just under threefold with both drugs. The team noted the limitations of their study and advised that it was interpreted with caution.
Industry representatives and medical societies were reported to have heavily criticised the methods of the original study – for example, saying that it did not include information about other factors that could affect the results (potential confounders)
A later analysis by the US Institute for Safe Medication Practices (ISMP) found that all five incretin mimetics were together associated with more than 25 times the rate of pancreatitis than that seen in people with diabetes taking other drugs. The DPP-4 inhibitors were associated with 13.5 times higher rates of pancreatic cancer, and the GLP-1 agonists had rates 23 times higher than other diabetic drugs.
For some of the drugs (linagliptin and saxagliptin) there was only a single case of pancreatic cancer, and changes in risk were not significant."

Information from the NHS here.  My bold text.

Eddie

No comments: